ABSTRACT

Antisense oligonucleotides (ONs) technology uses single stranded DNA to modulate gene expression. Antisense ONs with base sequences complementary to a specific mRNA can selectively modulate gene expression (1). Thus, antisense ONs may have potential as therapeutic agents against systemic and local diseases (2). Carcinoma, melanoma, psoriasis, xeroderma pigmentation, and viral diseases are potential candidates.